Fig. 6: The TGF-β2/Smad signaling pathway activation is required for KDM4C-mediated effects on tumor growth and radioresistance in lung cancer. | Cell Death & Differentiation

Fig. 6: The TGF-β2/Smad signaling pathway activation is required for KDM4C-mediated effects on tumor growth and radioresistance in lung cancer.

From: USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription

Fig. 6

a SPC-A1 cells transfected with indicated siRNAs in the absence or presence of 4 ng/ml TGF-β2 for 24 h were collected and analyzed by Western blotting using indicated antibodies (n = 3). b SPC-A1 cells treated with LY2109761 (10 μM), SD70 (3 μM) or a combination of both were collected and analyzed by immunoblotting (n = 3). c, d SPC-A1 cells treated with indicated siRNAs or drugs were seeded at low density in 6-well plates. Cell numbers were counted every other day. **P < 0.01, ***P < 0.001 (n = 3). e, f SPC-A1 cells treated with indicated siRNAs or drugs were plated in triplicates. Histograms representing the numbers of colonies are depicted. ***P < 0.001 (n = 3). n. s. indicates no statistically significant difference (P > 0.05, n = 3). g, h Neutral comet assay performed after exposure to irradiation. Left panel: Representative images show comet tail. Scale bar, 10 μm. Right panel: the olive tail moment was quantified and graphed for each group. ** P < 0.01, ***P < 0.001 (n = 3). i, j SPC-A1 cells treated with indicated siRNAs or drugs were irradiated using indicated doses. Colonies containing more than 50 cells were recorded after 2 weeks. **P < 0.01, ***P < 0.001 (n = 3).

Back to article page